Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching Zidovudine/Lamivudine to Tenofovir/Emtricitabine for Lipoatrophy in HIV
NCT00389194Phase 4Completed
- Sponsor
- International Antiviral Therapy Evaluation Center
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by International Antiviral Therapy Evaluation Center. Primary endpoint: Changes in subcutaneous and visceral abdominal fat and truncal fat at 48 weeks. Started Apr 2006; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00389194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389194.